Sign in
Not yet recruitingPhase 3

Model-informed precision dosing for linezolid: a randomized clinical trial

Key facts

Who runs it
University Medical Center Hamburg-Eppendorf
Where
Germany1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
30 people, planned
Started
1 Aug 2026
Expected to end
31 Jul 2028
Type of study
Interventional
Record updated
13 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adult trial participants a) ≥ 18 years of age b) Linezolid treatment is indicated or has been started due to pneumonia, skin or soft tissue infection; the patient has received no more than 2 infusions of 600 mg linezolid each
  • Participation a) with written informed consent of the patient or, Alternatively, but only if the patient is temporarily incapable of giving informed consent b) with written informed consent of his/her legally designated representative or c) after using the option of inclusion via spouse according to § 1358 BGB or d) according to article 35 of the CTR and with obtaining the patients informed consent as soon as possible
  • Patients with potential childbearing ability: negative pregnancy test

Who cannot take part

  • Concomitant treatment with monoamine oxidase inhibitors (e.g. phenelzine, isocarboxazid, tranylcypromine, moclobemide or selegiline)
  • Previous participation in this study
  • Infection other than pneumonia, skin or soft tissue infection, especially tuberculosis, endocarditis and osteomyelitis
  • Patients whose life expectancy is less than 7 days
  • Pregnancy
  • Lactation/breastfeeding
  • Simultaneous participation or participation in the past 4 weeks in another clinical trial with other medicinal products

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine whether model-informed precision dosing optimizes linezolid dosing in order to better achieve a therapeutic trough concentration compared to standard dosing.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
13 July 2026